Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00046319 · ClinicalTrials.gov registry record · Phase 2
Study of BSF 208075 Evaluating Exercise Capacity in Patients With Pulmonary Arterial Hypertension
A Phase 2 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT00046319 is a Phase 2 study that has completed, run by Gilead Sciences. The registered enrollment target is 60 participants.
The verdict
NCT00046319, a Phase 2 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if treating patients suffering from moderate to severe pulmonary arterial hypertension with BSF 208075 will improve the patients' ability to exercise.
Interventions
- DRUG BSF 208075
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2002-09 |
| Est. Completion | 2003-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00046319
The ClinicalTrials.gov registry entry for NCT00046319 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BSF 208075 is the first listed.
NCT00046319 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00046319 about?
NCT00046319 is a clinical study titled "Study of BSF 208075 Evaluating Exercise Capacity in Patients With Pulmonary Arterial Hypertension". The purpose of this study is to determine if treating patients suffering from moderate to severe pulmonary arterial hypertension with BSF 208075 will improve the patients' ability to exercise.
What is the current status of trial NCT00046319?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2002-09. Estimated completion is 2003-06.
What interventions are being tested in trial NCT00046319?
The interventions under investigation include: BSF 208075 (DRUG).
Who is sponsoring clinical trial NCT00046319?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.